^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Actinium-225 DOTATATE (RYZ101)

i
Other names: RYZ101, Actinium 225 radiolabeled somatostatin analog, 225Ac-DOTATATE, RYZ 101, RYZ-101
Company:
BMS
Drug class:
Alpha radiation emitter, SSTR2 inhibitor
2ms
New P1/2 trial • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Actinium-225 DOTATATE (RYZ101)
3ms
Enrollment open • Metastases
|
SSTR (Somatostatin Receptor)
|
sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101)
6ms
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC (clinicaltrials.gov)
P1, N=31, Recruiting, RayzeBio, Inc. | Trial primary completion date: Apr 2024 --> Mar 2025
Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1) • SSTR (Somatostatin Receptor)
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)
7ms
Enrollment closed • Metastases
|
SSTR (Somatostatin Receptor)
|
sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide acetate
7ms
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC (clinicaltrials.gov)
P1, N=31, Recruiting, RayzeBio, Inc. | Phase classification: P1b --> P1
Phase classification • Combination therapy
|
PD-L1 (Programmed death ligand 1) • SSTR (Somatostatin Receptor)
|
SSTR positive
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)
11ms
Trial completion date • Trial primary completion date • Metastases
|
SSTR (Somatostatin Receptor)
|
sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide acetate
12ms
Phase classification • Metastases
|
SSTR (Somatostatin Receptor)
|
sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide acetate
1year
Enrollment change • Metastases
|
SSTR (Somatostatin Receptor)
|
sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide acetate
1year
RYZ101 (Ac-225 DOTATATE) Opportunity Beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small Cell Lung Cancer. (PubMed, Mol Cancer Ther)
The anti-tumor effect was further enhanced when RYZ101 was combined with carboplatin and etoposide at clinically relevant doses. In summary, RYZ101 is a highly potent, alpha-emitting radiopharmaceutical agent, and preclinical data demonstrate the potential of RYZ101 for the treatment of patients with SSTR-positive cancers.
Preclinical • Journal
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
SSTR positive • SSTR2 expression • SSTR Expression • SSTR2 positive
|
carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)
over1year
Phase Ib portion of the ACTION-1 phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings (ESMO 2023)
Initial data suggest promising efficacy. Part 2 (phase 3) is enrolling and will compare RYZ101 at 10.2MBq q8w for 4 cycles with standard of care in pts with advanced SSTR2+ GEP-NETs progressing following prior 177Lu-labeled SSAs.
Clinical • P1 data
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
Actinium-225 DOTATATE (RYZ101)
over1year
RYZ101 (Ac-225 DOTATATE) Opportunity Beyond GEP-NETs: Preclinical Efficacy in Small Cell Lung Cancer (IASLC-WCLC 2023)
In summary, RYZ101 is a first-in-class, highly potent, -emitting radiopharmaceutical therapy being developed for the treatment of SSTR+ solid tumors. Preclinical data demonstrate the potential of RYZ101 for the treatment of patients with SSTR+ SCLC. A Phase 1b trial of RYZ101 in combination with atezolizumab, carboplatin, and etoposide is underway in patients with SSTR+ ES-SCLC (NCT05595460).
Preclinical • PD(L)-1 Biomarker
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
SSTR Expression
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)
over1year
ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis. (ASCO 2023)
RYZ101 was well tolerated at 120 kBq/kg, which was declared the RP3D. Part 2 (Phase 3) will commence after Part 1 and will compare RYZ101 at the RP3D with standard of care in pts with advanced SSTR2+ GEP-NETs with disease progression following prior 177Lu-labeled SSAs. Clinical trial information: NCT05477576.
Clinical
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
SSTR2 expression
|
Actinium-225 DOTATATE (RYZ101)
over1year
Enrollment open • Metastases
|
SSTR (Somatostatin Receptor)
|
sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide acetate
over1year
Anti-tumor activity of RYZ101 (Ac-225 DOTATATE) in somatostatin receptor-expressing preclinical models of small-cell lung cancer (AACR 2023)
In summary, RYZ101 is a first-in-class, highly potent, α-emitting radiopharmaceutical therapy being developed for the treatment of SSTR+ solid tumors. Preclinical data demonstrate the potential of RYZ101 for the treatment of patients with SSTR+ SCLC.
Preclinical
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
SSTR Expression
|
carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)
over1year
Enrollment closed • Metastases
|
SSTR (Somatostatin Receptor)
|
sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide acetate
almost2years
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC (clinicaltrials.gov)
P1b, N=31, Recruiting, RayzeBio, Inc. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy
|
PD-L1 (Programmed death ligand 1) • SSTR (Somatostatin Receptor)
|
SSTR positive
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)
2years
ACTION-1: A Randomized Phase Ib/3 trial of RYZ101 Compared with SoC in SSTR2+ Well-Differentiated GEP-NET with Progression Following Lu-177 SSA (NANETS 2022)
In Part 2, ~210 patients will be randomized (1:1) to receive RYZ101 RP3D every 8 weeks for up to 4 cycles or investigator’s choice SoC (everolimus, sunitinib, or high-dose long-acting SSA); crossover to RYZ101 is permitted. Part 2 will commence after Part 1 at ~60 sites in North America, South America, Europe, and Asia. CONCLUSIONS No conclusions; TiP abstract.
Clinical
|
SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
|
SSTR Expression
|
sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101)
2years
New P1 trial • Combination therapy
|
PD-L1 (Programmed death ligand 1) • SSTR (Somatostatin Receptor)
|
SSTR positive
|
Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)
over2years
New P1 trial
|
SSTR (Somatostatin Receptor)
|
sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • Somatuline Depot (lanreotide prolonged-release subcutaneous) • octreotide acetate